The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems

By Walczak H.   Krammer P.H.  

Experimental Cell Research, Vol. 256, Iss. 1, 2000-04 ,pp. : 58-66

Elsevier

Access to resources Recommend Favorite

Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade

By Reddy Rishindra   Yeow Wen-Shuz   Chua Alex   Nguyen Duc   Baras Aris   Ziauddin M.   Shamimi-Noori Susan   Maxhimer Justin   Schrump David   Nguyen Dao  

Apoptosis, Vol. 12, Iss. 1, 2007-01 ,pp. : 55-71

Springer Publishing Company

Access to resources Recommend Favorite

Death to the bad guys: Targeting cancer via Apo2L/TRAIL

By Bouralexis S.  

Apoptosis, Vol. 10, Iss. 1, 2005-01 ,pp. : 35-51

Springer Publishing Company

Access to resources Recommend Favorite

Induction of necrotic tumor cell death by TRAIL/Apo-2L

By Kemp T. J.   Kim J.-S.   Crist S. A.   Griffith T. S.  

Apoptosis, Vol. 8, Iss. 6, 2003-12 ,pp. : 587-599

Springer Publishing Company

Access to resources Recommend Favorite

Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor

By Ray S.   Bucur O.   Almasan A.  

Apoptosis, Vol. 10, Iss. 6, 2005-12 ,pp. : 1411-1418

Springer Publishing Company

Access to resources Recommend Favorite